Literature DB >> 14722896

Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

Ludo Lavreys1, Jared M Baeten, Joan K Kreiss, Barbra A Richardson, Bhavna H Chohan, Wisal Hassan, Dana D Panteleeff, Kishorchandra Mandaliya, Jeckoniah O Ndinya-Achola, Julie Overbaugh.   

Abstract

We examined the association between host factors present near the time of human immunodeficiency virus type 1 (HIV-1) acquisition and subsequent virus loads, in a prospective cohort study of women in Mombasa, Kenya. Women were prospectively followed monthly before HIV-1 infection. One hundred sixty-one commercial sex workers who became infected with HIV-1 were followed for a median of 34 months, and 991 plasma samples collected > or =4 months after infection were tested for HIV-1 RNA. The median virus set point at 4 months after infection was 4.46 log10 copies/mL, and the average virus load increase during subsequent follow-up was 0.0094 log10 copies/mL/month. In a multivariate analysis that controlled for sexual behavior, the use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) at the time of HIV-1 infection was associated with a higher virus set point, and the presence of genital ulcer disease (GUD) during the early phase of HIV-1 infection was associated with greater change in virus load during follow-up. These findings suggest that, in women, the use of DMPA and the presence of GUD during the early phase of HIV-1 infection may influence the natural course of infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722896     DOI: 10.1086/380974

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Effect of hormonal contraceptive use on HIV progression in female HIV seroconverters in Rakai, Uganda.

Authors:  Chelsea B Polis; Maria J Wawer; Noah Kiwanuka; Oliver Laeyendecker; Joseph Kagaayi; Tom Lutalo; Fred Nalugoda; Godfrey Kigozi; David Serwadda; Ronald H Gray
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

2.  Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe.

Authors:  Charles S Morrison; Pai-Lien Chen; Immaculate Nankya; Anne Rinaldi; Barbara Van Der Pol; Yun-Rong Ma; Tsungai Chipato; Roy Mugerwa; Megan Dunbar; Eric Arts; Robert A Salata
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

3.  Short communication: Fc gamma receptors IIa and IIIa genetic polymorphisms do not predict HIV-1 disease progression in Kenyan women.

Authors:  Julie F Weis; R Scott McClelland; Walter Jaoko; Kishor N Mandaliya; Julie Overbaugh; Susan M Graham
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11-13       Impact factor: 2.205

Review 4.  Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites.

Authors:  Olivia J Hall; Sabra L Klein
Journal:  Mucosal Immunol       Date:  2017-04-12       Impact factor: 7.313

5.  The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Authors:  Nicholas M Provine; Valerie Cortez; Vrasha Chohan; Julie Overbaugh
Journal:  Virology       Date:  2012-02-25       Impact factor: 3.616

6.  Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression.

Authors:  Susan M Graham; Nimerta Rajwans; Walter Jaoko; Benson B A Estambale; R Scott McClelland; Julie Overbaugh; W Conrad Liles
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

Review 7.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

Review 8.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

9.  Hormonal contraceptive use and risk of HIV-1 disease progression.

Authors:  Renee Heffron; Nelly Mugo; Kenneth Ngure; Connie Celum; Deborah Donnell; Edwin Were; Helen Rees; James Kiarie; Jared M Baeten
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

10.  Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif.

Authors:  Anne Piantadosi; Daryl Humes; Bhavna Chohan; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.